Renata Baffelli1, Lucia D Notarangelo2, Luisa Imberti3, Michael S Hershfield4, Federico Serana3, Ines Santisteban4, Federica Bolda1, Fulvio Porta2, Arnalda Lanfranchi5. 1. Stem Cell Laboratory, Section of Hematology and Blood Coagulation, Children's Hospital, Spedali Civili of Brescia, Brescia, Italy. 2. Pediatric Onco-Haematology and BMT Unit, Children's Hospital, Spedali Civili of Brescia, Brescia, Italy. 3. Centro Ricerca Emato-oncologica AIL (CREA), Diagnostics Department, Spedali Civili of Brescia, Brescia, Italy. 4. Department of Medicine, Duke University Medical Center, Durham, NC, USA. 5. Stem Cell Laboratory, Section of Hematology and Blood Coagulation, Children's Hospital, Spedali Civili of Brescia, Brescia, Italy. arnalda.lanfranchi@spedalicivili.brescia.it.
Abstract
PURPOSE: We carried out a retrospective analysis of 27 patients with Adenosine Deaminase (ADA) deficiency diagnosed in a single center from 1997 to the 2013, for evaluating whether data regarding types of disease-inducing mutations, biochemical and immunological features as well as clinical outcomes of patients treated with enzyme replacement or transplantation, were comparable to those obtained in multicenter studies. METHODS: The ADA deficiency diagnosis was performed with biochemical, immunological and molecular techniques. Ten patients treated with hematopoietic stem cell transplantation and three in treatment with enzyme replacement were followed up in our center. RESULTS: Twenty-four different mutations were identified and five were not previously reported. Identical mutations were found among patients from the same Romani ethnic group or from the same geographical region. A more rapid recovery was observed in enzyme replacement treated patients in comparison with those transplanted that, however, showed a continuous and long-lasting improvement both in terms of immune and metabolic recovery. CONCLUSION: The data obtained in our single center are comparable with those that have been reported in multicenter surveys.
PURPOSE: We carried out a retrospective analysis of 27 patients with Adenosine Deaminase (ADA) deficiency diagnosed in a single center from 1997 to the 2013, for evaluating whether data regarding types of disease-inducing mutations, biochemical and immunological features as well as clinical outcomes of patients treated with enzyme replacement or transplantation, were comparable to those obtained in multicenter studies. METHODS: The ADA deficiency diagnosis was performed with biochemical, immunological and molecular techniques. Ten patients treated with hematopoietic stem cell transplantation and three in treatment with enzyme replacement were followed up in our center. RESULTS: Twenty-four different mutations were identified and five were not previously reported. Identical mutations were found among patients from the same Romani ethnic group or from the same geographical region. A more rapid recovery was observed in enzyme replacement treated patients in comparison with those transplanted that, however, showed a continuous and long-lasting improvement both in terms of immune and metabolic recovery. CONCLUSION: The data obtained in our single center are comparable with those that have been reported in multicenter surveys.
Authors: Patrick J Collins; Lori K Hennessy; Craig S Leibelt; Rhonda K Roby; Dennis J Reeder; Paul A Foxall Journal: J Forensic Sci Date: 2004-11 Impact factor: 1.832
Authors: Elke Lainka; Michael S Hershfield; Ines Santisteban; Pawan Bali; Annette Seibt; Jennifer Neubert; Wilhelm Friedrich; Tim Niehues Journal: Clin Diagn Lab Immunol Date: 2005-07
Authors: I Santisteban; F X Arredondo-Vega; S Kelly; M Debre; A Fischer; J L Pérignon; B Hilman; J elDahr; D H Dreyfus; E W Gelfand Journal: Hum Mutat Date: 1995 Impact factor: 4.878
Authors: T Ariga; N Oda; I Sanstisteban; F X Arredondo-Vega; M Shioda; H Ueno; K Terada; K Kobayashi; M S Hershfield; Y Sakiyama Journal: J Immunol Date: 2001-02-01 Impact factor: 5.422
Authors: H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo Journal: Blood Date: 2009-07-28 Impact factor: 22.113
Authors: M S Hershfield; R H Buckley; M L Greenberg; A L Melton; R Schiff; C Hatem; J Kurtzberg; M L Markert; R H Kobayashi; A L Kobayashi Journal: N Engl J Med Date: 1987-03-05 Impact factor: 91.245
Authors: Immacolata Brigida; Aisha V Sauer; Francesca Ferrua; Stefania Giannelli; Samantha Scaramuzza; Valentina Pistoia; Maria Carmina Castiello; Barbara H Barendregt; Maria Pia Cicalese; Miriam Casiraghi; Chiara Brombin; Jennifer Puck; Klaus Müller; Lucia Dora Notarangelo; Davide Montin; Joris M van Montfrans; Maria Grazia Roncarolo; Elisabetta Traggiai; Jacques J M van Dongen; Mirjam van der Burg; Alessandro Aiuti Journal: J Allergy Clin Immunol Date: 2014-02-05 Impact factor: 10.793
Authors: Maria Pia Cicalese; Francesca Ferrua; Laura Castagnaro; Roberta Pajno; Federica Barzaghi; Stefania Giannelli; Francesca Dionisio; Immacolata Brigida; Marco Bonopane; Miriam Casiraghi; Antonella Tabucchi; Filippo Carlucci; Eyal Grunebaum; Mehdi Adeli; Robbert G Bredius; Jennifer M Puck; Polina Stepensky; Ilhan Tezcan; Katie Rolfe; Erika De Boever; Rickey R Reinhardt; Jonathan Appleby; Fabio Ciceri; Maria Grazia Roncarolo; Alessandro Aiuti Journal: Blood Date: 2016-04-29 Impact factor: 22.113
Authors: Donald B Kohn; Michael S Hershfield; Jennifer M Puck; Alessandro Aiuti; Annaliesse Blincoe; H Bobby Gaspar; Luigi D Notarangelo; Eyal Grunebaum Journal: J Allergy Clin Immunol Date: 2018-09-05 Impact factor: 10.793
Authors: Maria Pia Cicalese; Francesca Ferrua; Laura Castagnaro; Katie Rolfe; Erika De Boever; Rickey R Reinhardt; Jonathan Appleby; Maria Grazia Roncarolo; Alessandro Aiuti Journal: Mol Ther Date: 2018-01-04 Impact factor: 11.454
Authors: Carolyn H Baloh; Samiksha A Borkar; Kai-Fen Chang; Jiqiang Yao; Michael S Hershfield; Suhag H Parikh; Donald B Kohn; Maureen M Goodenow; John W Sleasman; Li Yin Journal: J Clin Immunol Date: 2021-06-28 Impact factor: 8.317